| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Over the last 12 months, insiders at Rigel Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Rigel Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Rigel Pharmaceuticals, Inc. have bought $688,400 and sold $192,509 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,000,000 shares for transaction amount of $688,400 was made by RODRIGUEZ RAUL R (CEO, President) on 2022‑06‑09.
| 2025-02-05 | Sale | RODRIGUEZ RAUL R | CEO, President | 4,400 0.0263% | $21.93 | $96,474 | +19.88% | |
| 2025-02-05 | Sale | Schorno Dean L | EVP & Chief Financial Officer | 1,734 0.0103% | $21.93 | $38,020 | +19.88% | |
| 2025-02-05 | Sale | Santos David A | EVP, Chief Commercial Officer | 1,796 0.0107% | $21.93 | $39,379 | +19.88% | |
| 2025-02-05 | Sale | Furey Raymond J. | EVP, GC, CCO & Corp Sec | 1,339 0.008% | $21.93 | $29,359 | +19.88% | |
| 2025-02-04 | Sale | RODRIGUEZ RAUL R | CEO, President | 4,952 0.0278% | $20.92 | $103,601 | +28.62% | |
| 2025-02-04 | Sale | Schorno Dean L | EVP & Chief Financial Officer | 2,036 0.0114% | $20.92 | $42,595 | +28.62% | |
| 2025-02-04 | Sale | Santos David A | EVP, Chief Commercial Officer | 2,125 0.0119% | $20.92 | $44,457 | +28.62% | |
| 2025-02-04 | Sale | Furey Raymond J. | EVP, GC, CCO & Corp Sec | 1,448 0.0081% | $20.92 | $30,294 | +28.62% | |
| 2024-02-05 | Sale | RODRIGUEZ RAUL R | CEO, President | 30,545 0.016% | $1.14 | $34,821 | +14.62% | |
| 2024-02-05 | Sale | Schorno Dean L | EVP & Chief Financial Officer | 7,027 0.0037% | $1.14 | $8,011 | +14.62% | |
| 2024-02-05 | Sale | Santos David A | EVP, Chief Commercial Officer | 8,918 0.0047% | $1.14 | $10,167 | +14.62% | |
| 2024-02-02 | Sale | RODRIGUEZ RAUL R | CEO, President | 22,349 0.0116% | $1.13 | $25,261 | +17.54% | |
| 2024-02-02 | Sale | Schorno Dean L | EVP & Chief Financial Officer | 5,601 0.0029% | $1.13 | $6,327 | +17.54% | |
| 2024-02-02 | Sale | Santos David A | EVP, Chief Commercial Officer | 5,601 0.0029% | $1.13 | $6,329 | +17.54% | |
| 2023-02-06 | Sale | RODRIGUEZ RAUL R | CEO, President | 20,340 0.012% | $1.75 | $35,595 | -26.90% | |
| 2023-02-02 | Sale | Schorno Dean L | EVP & Chief Financial Officer | 5,389 0.0029% | $1.66 | $8,946 | -28.81% | |
| 2023-02-02 | Sale | Santos David A | EVP, Chief Commercial Officer | 5,388 0.0029% | $1.66 | $8,945 | -28.81% | |
| 2023-02-02 | Sale | Dummer Wolfgang | EVP & CMO | 5,389 0.0029% | $1.66 | $8,946 | -28.81% | |
| 2022-06-09 | RODRIGUEZ RAUL R | CEO, President | 1M 0.5572% | $0.69 | $688,400 | +76.88% | ||
| 2019-05-22 | Schorno Dean L | EVP &Chief Financial Officer | 50,000 0.0311% | $2.13 | $106,544 | +2.44% |
| MPM BIOEQUITIES MASTER FUND LP | 10 percent owner | 4350516 23.9681% | $154.66M | 0 | 1 | |
| Flynn James E | 10 percent owner | 3204167 17.6525% | $113.91M | 1 | 1 | <0.0001% |
| STEINMETZ MICHAEL | 10 percent owner | 1833597 10.1017% | $65.18M | 0 | 1 | |
| GALAKATOS NICHOLAS | 10 percent owner | 1833597 10.1017% | $65.18M | 0 | 1 | |
| EVNIN LUKE | 10 percent owner | 1687072 9.2945% | $59.98M | 0 | 26 | |
| MPM BIOVENTURES III QP LP | 10 percent owner | 1687072 9.2945% | $59.98M | 0 | 26 | |
| BVF PARTNERS L P/IL | 10 percent owner | 646559 3.5621% | $22.99M | 1 | 1 | <0.0001% |
| RODRIGUEZ RAUL R | CEO, President | 239454 1.3192% | $8.51M | 2 | 6 | +34.43% |
| Mayer Eldon C. III | EVP & Chief Commercial Officer | 215000 1.1845% | $7.64M | 3 | 0 | <0.0001% |
| Dummer Wolfgang | EVP & CMO | 72459 0.3992% | $2.58M | 0 | 1 | |
| Schorno Dean L | EVP & Chief Financial Officer | 57235 0.3153% | $2.03M | 1 | 5 | +2.44% |
| PAYAN DONALD G | EVP, Pres. Discovery&Research | 53031 0.2922% | $1.89M | 0 | 6 | |
| Santos David A | EVP, Chief Commercial Officer | 51704 0.2849% | $1.84M | 0 | 5 | |
| Furey Raymond J. | EVP, GC, CCO & Corp Sec | 38830 0.2139% | $1.38M | 0 | 2 | |
| DELEAGE JEAN | director | 11604 0.0639% | $412,522.20 | 0 | 26 | |
| Goodwin Bradford S | director | 10000 0.0551% | $355,500.00 | 1 | 0 | +109.25% |
| COOPER ROBIN D G | Sr. V.P. Pharmaceutical Scs. | 9000 0.0496% | $319,950.00 | 5 | 0 | +47.09% |
| ALTA PARTNERS II INC | 10 percent owner | 8050 0.0443% | $286,177.50 | 0 | 15 | |
| FRAZIER HEALTHCARE IV LP | 10 percent owner | 6180 0.034% | $219,699.00 | 0 | 1 | |
| WELCH JAMES H | CFO, VP & Secretary | 3757 0.0207% | $133,561.35 | 0 | 1 | |
| Grossbard Elliott B | Sr. VP Medical Development | 2000 0.011% | $71,100.00 | 1 | 0 | +4.66% |
| GADICKE ANSBERT | 10 percent owner | 1447 0.008% | $51,440.85 | 0 | 1 | |
| VANCE DOLLY | EVP Corp. Affairs, G.C., Sect. | 575 0.0032% | $20,441.25 | 1 | 3 | |
| Cabatuan Nelson | Principal Accounting Officer | 58 0.0003% | $2,061.90 | 0 | 1 | |
| FRAZIER ALAN D | director | 0 0% | $0 | 0 | 4 | |
| SIMON NICHOLAS J III | director | 0 0% | $0 | 0 | 27 | |
| HENNER DENNIS | director | 0 0% | $0 | 0 | 27 | |
| Maynard Ryan D | EVP & CFO | 0 0% | $0 | 0 | 5 | |
| Duliege Anne-Marie | EVP & Chief Medical Officer | 0 0% | $0 | 0 | 6 |
$3,611,891 | 113 | 13.40% | $568.07M | |
$96,660,103 | 38 | -2.10% | $757.69M | |
$63,049,419 | 31 | 2.87% | $591.5M | |
$7,598,498 | 27 | 34.68% | $764.21M | |
$24,857,912 | 21 | -35.40% | $716.77M | |
$46,858,891 | 18 | -11.58% | $576.47M | |
$59,102,045 | 17 | 8.52% | $602.76M | |
Rigel Pharmaceuticals, Inc. (RIGL) | $7,254,955 | 14 | 20.70% | $645.28M |
$92,357,691 | 12 | 87.24% | $669.7M | |
$75,069,528 | 10 | 19.77% | $568.45M | |
$11,541,901 | 10 | 8.07% | $737.91M | |
$140,543,039 | 10 | 0.77% | $610.12M | |
$19,167,169 | 10 | 28.48% | $576.83M | |
$38,624,786 | 9 | 1.26% | $720.14M | |
$160,798,946 | 8 | -3.92% | $794.55M | |
$49,165,200 | 7 | 12.92% | $599.48M | |
$94,000,000 | 7 | -20.84% | $597.49M | |
$7,234,370 | 3 | -3.34% | $651.27M | |
$33,624,000 | 2 | -50.37% | $771.33M |
| Increased Positions | 121 | +76.58% | 4M | +29.2% |
| Decreased Positions | 72 | -45.57% | 3M | -17.79% |
| New Positions | 62 | New | 2M | New |
| Sold Out Positions | 21 | Sold Out | 481,972 | Sold Out |
| Total Postitions | 207 | +31.01% | 16M | +11.42% |
| Blackrock, Inc. | $72,152.00 | 9.58% | 1.72M | +99,128 | +6.1% | 2025-09-30 |
| Vanguard Group Inc | $43,634.00 | 5.8% | 1.04M | -9,748 | -0.93% | 2025-09-30 |
| Goldman Sachs Group Inc | $30,830.00 | 4.1% | 737,035 | +554,786 | +304.41% | 2025-09-30 |
| Armistice Capital, Llc | $30,285.00 | 4.02% | 724,000 | -876,000 | -54.75% | 2025-09-30 |
| Acadian Asset Management Llc | $28,684.00 | 3.81% | 685,718 | +62,714 | +10.07% | 2025-09-30 |
| Marshall Wace, Llp | $25,154.00 | 3.34% | 601,333 | +232,383 | +62.98% | 2025-09-30 |
| Capitolis Liquid Global Markets Llc | $24,745.00 | 3.29% | 591,553 | 0 | 0% | 2025-09-30 |
| State Street Corp | $23,187.00 | 3.08% | 554,318 | -45,863 | -7.64% | 2025-09-30 |
| Renaissance Technologies Llc | $19,836.00 | 2.63% | 474,209 | +237,763 | +100.56% | 2025-09-30 |
| Geode Capital Management, Llc | $17,724.00 | 2.35% | 423,723 | +8,116 | +1.95% | 2025-09-30 |